Services-Commercial Physical & Biological Research · SIC 8731
Cannabis Bioscience International Holdings, Inc.
CBIH
Latest revenue
$11.2K
as of 2026-02-28
Latest net income
$-103.9K
as of 2026-02-28
Net margin
-927.6%
as of 2026-02-28
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $3.5M
- Enterprise value
- $3.5M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.00
- 52-wk low
- $0.00
- Beta
- —
- Shares out
- 11.63B
5-year trend
What this company does
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. The financial data discussed below are derived from the unaudited consolidated financial statements of the Company as of February 28, 2026, which were prepared and presented in accordance with United States generally accepted accounting principles for interim financial statements. These financial data are only a summary and should be read in conjunction with the unaudited financial statements and related notes contained herein, which more fully present the Company’s financial condition and operations as at that date and with its audited financial statements and notes thereto contained in its…
AI summary unavailable — showing raw filing excerpt
Generated from CBIH's filing dated 2026-04-16
Key risks
Item 1A. Risk Factors. The Company is a smaller reporting company as defined by Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the “Exchange Act”) and accordingly is not required to provide information under this item.
AI summary unavailable — showing raw filing excerpt
Generated from CBIH's filing dated 2026-04-16
Profitability
Gross margin
86.8%
6.2%Operating margin
-139.1%
28.8%Net margin
-181.1%
30.8%Return on equity
47.2%
21.9%Return on assets
-1721.5%
51.1%Leverage
Debt / equity
-1.03×
2.4%Long-term debt / equity
-0.21×
7.2%Debt / assets
3749.9%
88.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-02-28 | $11.2K | -25.0% | $-103.9K | +42.7% | -927.6% |
Q4 2025 2025-11-30 | $53.3K | -28.3% | $-117.0K | -47.1% | -219.6% |
Q3 2025 2025-08-31 | $24.2K | -86.5% | $-82.6K | -8.3% | -341.5% |
Q2 2025 2025-05-31 | $35.0K | -53.9% | $-211.7K | -55.8% | -605.7% |
Q1 2025 2025-02-28 | $14.9K | -59.0% | $-181.2K | +13.4% | -1213.9% |
Q4 2024 2024-11-30 | $74.2K | +16.5% | $-79.5K | +36.1% | -107.1% |
Q3 2024 2024-08-31 | $178.9K | +145.7% | $-76.3K | +58.0% | -42.7% |
Q2 2024 2024-05-31 | $75.9K | — | $-135.9K | — | -179.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Commercial Physical & Biological Research · SIC 8731
Your notes
Keep private notes on CBIH — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for CBIH in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns CBIH
No institutional holdings on file for CBIH yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once CBIH's latest filing finishes processing.